Extended-release ciprofloxacin (Cipro XR) for treatment of urinary tract infections

International Journal of Antimicrobial Agents

Volumn 23, Issue SUPPL. 1, 2004, Pages 54-66

  Talan, David A ^a   Naber, Kurt G ^b   Palou, Juan ^c   Elkharrat, David ^d  

^a OLIVE VIEW UCLA MEDICAL CENTER   (United States)

^b Urologische Klinik   (Germany)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^d HÔPITAL LARIBOISIÈRE   (France)

Author keywords

Ciprofloxacin; Trimethoprim sulphamethoxazole; Urinary tract infections

Indexed keywords

ANTACID AGENT; ANTIBIOTIC AGENT; CAFFEINE; CIPROFLOXACIN; COTRIMOXAZOLE; DIDANOSINE; OMEPRAZOLE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; THEOPHYLLINE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERICIDAL ACTIVITY; CONFERENCE PAPER; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG POTENCY; DRUG TOLERABILITY; ESCHERICHIA COLI; HUMAN; PATIENT COMPLIANCE; PHARMACODYNAMICS; PRIORITY JOURNAL; SEROPREVALENCE; SLOW RELEASE FORMULATION; URINARY TRACT INFECTION;

EID: 1642339626     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2003.12.005     Document Type: Conference Paper

References (51)

1. Warren J.W., Abrutyn E., Hebel J.R., Johnson J.R., Schaeffer A.J., Stamm W.E. Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Infectious Diseases Society of America (IDSA). Clin. Infect. Dis. 29:1999;745-758.
2. Foxman B. Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Am. J. Med. 113:2002;5S-13S.
3. Gales A.C., Jones R.N., Gordon K.A.et al. Activity and spectrum of 22 antimicrobial agents tested against urinary tract infection pathogens in hospitalized patients in Latin America: report from the second year of the SENTRY Antimicrobial Surveillance Program (1998). J. Antimicrob. Chemother. 45:2000;295-303.
4. Mazzulli T. Resistance trends in urinary tract pathogens and impact on management. J. Urol. 168:2002;1720-1722.
5. Foxman B., Barlow R., D'Arcy H., Gillespie B., Sobel J.D. Urinary tract infection: self-reported incidence and associated costs. Ann. Epidemiol. 10:2000;509-515.
6. Roberts WO. Urinary tract infections and the cost of antimicrobial resistance. A special report. Healthcare Information Programs. Postgrad Med 2001.
7. Barnett B.J., Stephens D.S. Urinary tract infection: an overview. Am. J. Med. Sci. 314:1997;245-249.
8. Hooton T.M. The current management strategies for community-acquired urinary tract infection. Infect. Dis. Clin. North Am. 17:2003;303-332.
9. Fihn S.D. Clinical practice. Acute uncomplicated urinary tract infection in women. N. Engl. J. Med. 349:2003;259-266.
10. Gordon K.A., Jones R.N. Susceptibility patterns of orally administered antimicrobials among urinary tract infection pathogens from hospitalised patients in North America: comparison report to Europe and Latin America. Results from the SENTRY Antimicrobial Surveillance Program (2000). Diagn. Microbiol. Infect. Dis. 45:2003;295-301.
11. Karlowsky J.A., Kelly L.J., Thornsberry C.et al. Susceptibility to fluoroquinolones among commonly isolated Gram-negative bacilli in 2000: TRUST and TSN data for the United States. Tracking resistance in the United States today. The surveillance network. Int. J. Antimicrob. Agents. 19:2002;21-31.
12. Karlowsky J.A., Kelly L.J., Thornsberry C., Jones M.E., Sahm D.F. Trends in antimicrobial resistance among urinary tract infection isolates of Escherichia coli from female outpatients in the United States. Antimicrob. Agents Chemother. 46:2002;2540-2545.
13. Stratton C. Fluoroquinolone antibiotics: properties of the class and individual agents. Clin. Ther. 14:1992;348-375.
14. Appelbaum P.C., Hunter P.A. The fluoroquinolone antibacterials: past, present and future perspective. Int. J. Antimicrob. Agents. 16:2000;5-15.
15. Naber K.G., Bergman B., Bishop M.C.et al. EAU guidelines for the management of urinary and male genital tract infections. Urinary Tract Infection (UTI) Working Group of the Health Care Office (HCO) of the European Association of Urology (EAU). Eur. Urol. 40:2001;576-588.
16. Gupta K., Hooton T.M., Stamm W.E. Increasing antimicrobial resistance and the management of uncomplicated community-acquired urinary tract infections. Ann. Intern. Med. 135:2001;41-50.
17. Davis R., Markham A., Balfour J.A. Ciprofloxacin. An updated review of its pharmacology, therapeutic efficacy and tolerability. Drugs. 51:1996;1019-1074.
18. Karlowsky J.A., Thornsberry C., Jones M.E., Sahm D.F. Susceptibility of antimicrobial-resistant urinary Escherichia coli isolates to fluoroquinolones and nitrofurantoin. Clin. Infect. Dis. 36:2003;183-187.
19. Farrell D.J., Morrissey I., De Rubeis D., Robbins M., Felmingham D. A UK multicentre study of the antimicrobial susceptibility of bacterial pathogens causing urinary tract infection. J. Infect. 46:2003;94-100.
20. Talan D.A., Stamm W.E., Hooton T.M.et al. Comparison of ciprofloxacin (7 days) and trimethoprim-sulfamethoxazole (14 days) for acute uncomplicated pyelonephritis in women: a randomized trial. J. Am. Med. Assoc. 283:2000;1583-1590.
21. Masterton R.G., Bochsler J.A. High-dosage co-amoxiclav in a single dose versus 7 days of co-trimoxazole as treatment of uncomplicated lower urinary tract infection in women. J. Antimicrob. Chemother. 35:1995;129-137.
22. McCarty J.M., Richard G., Huck W.et al. A randomized trial of short-course ciprofloxacin, ofloxacin, or trimethoprim/sulfamethoxazole for the treatment of acute urinary tract infection in women. Ciprofloxacin Urinary Tract Infection Group. Am. J. Med. 106:1999;292-299.
23. Raz R., Chazan B., Kennes Y.et al. Empiric use of trimethoprim- sulfamethoxazole (TMP-SMX) in the treatment of women with uncomplicated urinary tract infections, in a geographical area with a high prevalence of TMP-SMX-resistant uropathogens. Clin. Infect. Dis. 34:2002;1165-1169.
24. Henry D.C. Jr., Bettis R.B., Riffer E.et al. Comparison of once-daily extended-release ciprofloxacin and conventional twice-daily ciprofloxacin for the treatment of uncomplicated urinary tract infection in women. Clin. Ther. 24:2002;2088-2104.
25. Stamm W.E., Hooton T.M. Management of urinary tract infections in adults. N. Engl. J. Med. 329:1993;1328-1334.
26. Gupta K., Scholes D., Stamm W.E. Increasing prevalence of antimicrobial resistance among uropathogens causing acute uncomplicated cystitis in women. J. Am. Med. Assoc. 281:1999;736-738.
27. Jones R.N., Kugler K.C., Pfaller M.A., Winokur P.L. Characteristics of pathogens causing urinary tract infections in hospitals in North America: results from the SENTRY Antimicrobial Surveillance Program, 1997. Diagn. Microbiol. Infect. Dis. 35:1999;55-63.
28. Zhanel G.G., Karlowsky J.A., Harding G.K. A Canadian national surveillance study of urinary tract isolates from outpatients: comparison of the activities of trimethoprim-sulfamethoxazole, ampicillin, mecillinam, nitrofurantoin, and ciprofloxacin. The Canadian Urinary Isolate Study Group. Antimicrob. Agents Chemother. 44:2000;1089-1092.
29. Kahlmeter G. An international survey of the antimicrobial susceptibility of pathogens from uncomplicated urinary tract infections: the ECOSENS Project. J. Antimicrob. Chemother. 51:2003;69-76.
30. Wright S.W., Wrenn K.D., Haynes M.L. Trimethoprim-sulfamethoxazole resistance among urinary coliform isolates. J. Gen. Intern. Med. 14:1999;606-609.
31. Steinke D.T., Seaton R.A., Phillips G., MacDonald T.M., Davey P.G. Prior trimethoprim use and trimethoprim-resistant urinary tract infection: a nested case-control study with multivariate analysis for other risk factors. J. Antimicrob. Chemother. 47:2001;781-787.
32. Gupta K., Sahm D.F., Mayfield D., Stamm W.E. Antimicrobial resistance among uropathogens that cause community-acquired urinary tract infections in women: a nationwide analysis. Clin. Infect. Dis. 33:2001;89-94.
33. Nicolle L.E. Urinary tract infection: traditional pharmacologic therapies. Am. J. Med. 113:2002;35S-44S.
34. Morrissey I, Farrell DJ, Robbins M, Werling H-O, Felingham D. Surveillance of the antibiotic susceptibility of urinary tract infection (UTI) pathogens in Europe from outpatients (OUT) and inpatients (IN) during 1999/2000. Clin Microbiol Infect 2003;9(Suppl. 1):355 [abstract p 1459].
35. Pechere J.C. Parameters important in short antibiotic courses. J. Int. Med. Res. 28:2000;3A-12A.
36. Leclercq R. Safeguarding future antimicrobial options: strategies to minimize resistance. Clin. Microbiol. Infect. 7:2001;18-23.
37. Gould I.M., Milne K., Jason C. Concentration-dependent bacterial killing, adaptive resistance and post-antibiotic effect of ciprofloxacin alone and in combination with gentamicin. Drugs Exp. Clin. Res. 16:1990;621-628.
38. Lode H., Borner K., Koeppe P. Pharmacodynamics of fluoroquinolones. Clin. Infect. Dis. 27:1998;33-39.
39. Thomas J.K., Forrest A., Bhavnani S.M.et al. Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy. Antimicrob. Agents Chemother. 42:1998;521-527.
40. Harder S., Fuhr U., Beermann D., Staib A.H. Ciprofloxacin absorption in different regions of the human gastrointestinal tract. Investigations with the hf-capsule. Br. J. Clin. Pharmacol. 30:1990;35-39.
41. Theil FP, Frede M, Stass H. Population pharmacokinetic characterization of the new ciprofloxacin MR formulation with ciprofloxacin IR. Clin Microbiol Infect 2003;9(Suppl. 1):292 [abstract p 1228].
42. Cipro XR prescribing information. Bayer Pharmaceuticals, 2003.
43. Stass H., Nagelschmitz J., Brendel E., Kanikanti V.-R. Pharmacokinetics of a new ciprofloxacin once daily formulation for the treatment of complicated urinary tract infections. J. Investig. Med. 50:2002;155A. [abstract 25].
44. Stass H., Nagelschmitz J., Brendel E., Schuekler F. Pharmacokinetic characterization of a new ciprofloxacin once daily formulation for treatment of uncomplicated urinary tract infections. J. Investig. Med. 50:2002;155A. [abstract 24].
45. Stass H., Nagelschmitz J., Brendel E., Delesen H. The effect of food on the pharmacokinetics of a new ciprofloxacin once daily formulation for treatment of uncomplicated or complicated urinary tract infections. J. Investig. Med. 50:2002;154A. [abstract 23].
46. Sahm D.F., Thornsberry C., Kelly L.J.et al. In vitro activities of commonly used antibiotics against prevalent uropathogens: implications for empiric therapy. Infect. Urol. 14:2001;59-67.
47. Woodcock J.M., Andrews J.M., Boswell F.J., Brenwald N.P., Wise R. In vitro activity of BAY 12-8039, a new fluoroquinolone. Antimicrob. Agents Chemother. 41:1997;101-106.
48. Meagher AK, Forrest A, Dalhoff A, Stass H, Schentag JJ. A novel PK/PD model for prediction of outcomes with an extended release formulation of ciprofloxacin. In: Proceedings of the Interscience Conference on Antimicrobial Agents and Chemotherapy, 2002 [abstract A-1257].
49. Bayer Pharmaceuticals. Data on file.
50. Talan DA. American Urology Association, Chicago, 2003.
51. Bertino J. Jr., Fish D. The safety profile of the fluoroquinolones. Clin. Ther. 22:2000;798-817.